PharmaInformatic Homepage

Meet representatives of PharmaInformatic

To arrange a meeting, please contact us.

Direct access to all pages:

Site map

PharmaInformatic is a German biotech company, which provides ADME/Tox Knowledge Bases and predictive tools (Expert Systems) to improve drug discovery and development. The company was founded in 2004 by Dr. Wolfgang Boomgaarden and is based in Emden, Germany.

Current News - Launch of IMPACT-F:

A novel expert system to accelerate drug discovery is now available. The expert system IMPACT-F calculates oral bioavailability of future drugs in humans. Predictions were shown to be much more precise than animal trials: they were as accurate as the common deviation between individual humans taking part in the same clinical trial. Read our current research results on bioavailability of drugs.
Press release and images.

Every year, millions of animal experiments are carried out. Computational models such as IMPACT-F can replace animal trials: they require no experimental effort, are less expensive and results are almost immediately available. Since they are significantly more reliable than animal models, they will increase the prospects of successful clinical trials in humans.

In the News: German newspaper published a detailed report about PharmaInformatic and on the development of the knowledge base PACT-F (read more).

PACT-F, the largest knowledge base on bioavailability of drugs worldwide:

PharmaInformatic has developed a comprehensive knowledge base on bioavailability, which enables the targeted development of new drugs. The development of the knowledge base began in 2005. Since then the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database, read press release.

PACT-F is now the largest knowledge base on bioavailability worldwide. It contains 8296 records, which describe in detail the results of clinical trials in humans and preclinical trials in animals. PACT-F is extensively annotated: up to 17 fields describe in detail the results and conditions of each trial, see content of PACT-F.

Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development will be stopped.